A RETROSPECTIVE ANALYSIS OF SEQUENTIAL USE OF THE TYROSINE KINASE INHIBITORS (TKI) SORAFENIB (SOR) AND SUNITINIB (SUN) IN METASTATIC RENAL CELL CARCINOMA (mRCC)

被引：0
|
作者：
Calvani, N. [1 ,2 ]
Chetri, M. C. [1 ,2 ]
Cinefra, M. [1 ,2 ]
D'Amico, M. [1 ,2 ]
Fedele, P. [1 ,2 ]
Marino, M. [1 ,2 ]
Mazzoni, E. [1 ,2 ]
Nacci, A. [1 ,2 ]
Orlando, L. [1 ,2 ]
Rizzo, P. [1 ,2 ]
Schiavone, P. [1 ,2 ]
Sponziello, F. [1 ,2 ]
Cinieri, S. [1 ,2 ]
机构：
[1] A Perrino Hosp, Div Med Oncol, Brindisi, Italy
[2] A Perrino Hosp, Breast Unit, Brindisi, Italy
来源：
CANCER TREATMENT REVIEWS | 2010年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
14
引用
收藏
页码：S99 / S99
页数：1
相关论文
共 50 条
  • [1] Sequential Use of the Tyrosine Kinase Inhibitors Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma: A Retrospective Outcome Analysis
    Eichelberg, Christian
    Heuer, Roman
    Chun, Felix K.
    Hinrichs, Kristin
    Zacharias, Mario
    Huland, Hartwig
    Heinzer, Hans
    EUROPEAN UROLOGY, 2008, 54 (06) : 1373 - 1378
  • [2] Macrocytosis in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKI's)
    Khasawneh, M. F.
    Unnithan, J.
    Choueiri, T.
    Rini, B.
    Dreicer, R.
    Garcia, J.
    Wood, L.
    Elson, P.
    Bukowski, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] SEQUENTIAL THERAPY WITH SUNITINIB-SORAFENIB IN METASTATIC RENAL CELL CARCINOMA (MRCC): PRELIMINARY RESULTS
    Condorelli, Rosaria
    Buscarino, Calogero
    Ferrau, Francesco
    Novello, Giuseppe
    Vigneri, Paolo
    Restuccia, Nunzio
    Banna, Giuseppe Luigi
    ANNALS OF ONCOLOGY, 2009, 20
  • [4] Is there a role for immunotherapy (IO) and tyrosine kinase inhibitors (TKI) for older adults with metastatic renal cell carcinoma (mRCC)?
    Dizman, Nazli
    Bergerot, Paulo Gustavo
    Bergerot, Cristiane Decat
    Hsu, Joann
    Adashek, Jacob
    Dale, William
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Incidence and prognostic role of cumulative toxicity by tyrosine kinase inhibitors (TKI) in metastatic renal cell carcinoma (mRCC)
    Iacovelli, R.
    Rocca, M. Cossu
    Cullura, D.
    Aurilio, G.
    Verri, E.
    Crescio, C.
    Detti, S.
    De Cobelli, O.
    Nole, F.
    ANNALS OF ONCOLOGY, 2015, 26 : 56 - 56
  • [6] USE OF TYROSINE KINASE INHIBITORS (TKI) IN HAEMODIALYTIC METASTATIC RENAL CELL CARCINOMA PATIENTS
    Sabbatini, R.
    Porta, C.
    Procopio, G.
    Ferrari, A.
    Conte, P. F.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 185 - 185
  • [7] Incidence and prognostic role of cumulative toxicity by tyrosine kinase inhibitors (TKI) in metastatic renal cell carcinoma (mRCC)
    Iacovelli, R.
    Rocca, M. Cossu
    Aurilio, G.
    Cullura, D.
    Verri, E.
    Crescio, C.
    Detti, S.
    De Cobelli, O.
    Nole, F.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S522 - S522
  • [8] Hypogonadism in male cancer patients treated with the tyrosine kinase inhibitors sunitinib (SUN) or sorafenib (SOR)
    Wolter, P.
    Wildiers, H.
    Vanderschueren, D.
    Dumez, H.
    Clement, P.
    Schoffski, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Antitumor activity of sequential treatment with tyrosine kinase inhibitors (TKI) after failure of RAD001 in metastatic renal cell carcinoma (mRCC)
    Gruenwald, V.
    Fenner, M.
    Seidel, C.
    Heuser, M.
    Ganser, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Thyroid Dysfunction in Patients Treated with Tyrosine Kinase Inhibitors, Sunitinib, Sorafenib and Axitinib, for Metastatic Renal Cell Carcinoma
    Daimon, Makoto
    Kato, Tomoyuki
    Kaino, Wataru
    Takase, Kaoru
    Karasawa, Shigeru
    Wada, Kiriko
    Kameda, Wataru
    Susa, Shinji
    Oizumi, Toshihide
    Tomita, Yoshihiko
    Kato, Takeo
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (08) : 742 - 747
12345